Nearly a year ago we concluded that AI Drug Discovery Stocks Continue to Disappoint. The best examples are two names we cover closely that seemingly pivoted from “exciting AI-enabled drug discovery platforms” to “risky in-house drug developers.” Since then, the two have run equally in opposite directions with one up +36% and one down 36% […]
Source link










-1024x683.jpg)






